Tedizolid: A Novel Oxazolidinone for Gram-Positive Infections
Open Access
- 1 January 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (suppl_1) , S1-S3
Abstract
Despite the concerted efforts of modern medicine, infections due to gram-positive bacteria, such as skin and soft tissue infections, pneumonia, bacteremia, and endocarditis, continue to pose many challenges to achieving successful treatment outcomes. A good case in point is found in the emergence and spread of methicillin resistance in Staphylococcus aureus. The first strains of methicillin-resistant S. aureus (MRSA) were discovered a half-century ago in a hospital in London, just 2 years after the first clinical use of methicillin [1]. During the ensuing 50 years, these organisms have spread worldwide despite extensive attempts to control them. In some of the Scandinavian countries and the Netherlands, “search and destroy” efforts in hospitals have been successful in controlling infections caused by MRSA. This was aided by the fact that most MRSA infections were hospital acquired. That situation, however, began to change in the early 1990s, when infections due to MRSA were noted in patients without previous inpatient healthcare exposure across 6 different continents, including Australia, where several outbreaks were detected in Western Australia and the Northern Territory [2, 3]. Community-acquired (or community-associated) MRSA (CA-MRSA) subsequently spread throughout North America, where one particular clone (USA-300) quickly established dominance. Not surprisingly, these strains have also spread to Europe, where they have caused significant problems due to the fact that European guidelines for infection control have been geared to inpatient rather than outpatient acquisition of methicillin-resistant strains [4].Keywords
This publication has 15 references indexed in Scilit:
- Resistance to Linezolid Caused by Modifications at Its Binding Site on the RibosomeAntimicrobial Agents and Chemotherapy, 2012
- MRSA: the first half centuryJournal of Antimicrobial Chemotherapy, 2011
- Antibiotic resistance is ancientNature, 2011
- Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for TherapyClinical Infectious Diseases, 2011
- Discovering new antimicrobial agentsInternational Journal of Antimicrobial Agents, 2011
- Community-Associated Methicillin-ResistantStaphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging EpidemicClinical Microbiology Reviews, 2010
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Acquisition of a natural resistance gene renders a clinical strain of methicillin‐resistantStaphylococcus aureusresistant to the synthetic antibiotic linezolidMolecular Microbiology, 2007
- Oxazolidinones: New antibacterial agentsTrends in Microbiology, 1997
- RECOVERY OF RESISTANCE (R) FACTORS FROM A DRUG-FREE COMMUNITYThe Lancet, 1969